<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2941">
  <stage>Registered</stage>
  <submitdate>5/10/2010</submitdate>
  <approvaldate>5/10/2010</approvaldate>
  <nctid>NCT01215643</nctid>
  <trial_identification>
    <studytitle>Efficacy and Safety of Alisporivir Alone or Combined With RBV or PEG in Chronic Hepatitis C Genotype 2 and 3 Treatment-naïve Participants</studytitle>
    <scientifictitle>A Multicenter, Randomized, Open Label, Parallel-group Phase IIB Study on the Efficacy and Safety of Oral Regimens of DEB025 Alone or in Combination With Ribavirin Versus Standard of Care (Peg-IFNa2a Plus Ribavirin) in Treatment-naïve Hepatitis C Genotype 2 and 3 Patients</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2010-020034-26</secondaryid>
    <secondaryid>CDEB025A2211</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hepatitis C</healthcondition>
    <healthcondition>Chronic Pain</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Alisporivir
Treatment: drugs - Peginterferon alfa-2a
Treatment: drugs - Ribavirin

Experimental: ALV 1000 mg - Alisporivir (ALV) 600 mg twice daily (BID) for 1 week, followed by ALV 1000 mg once daily (QD) during Weeks 2 to 24.

Experimental: ALV 600 mg+RBV - Alisporivir (ALV) 600 mg BID with RBV for 1 week, followed by ALV 600 mg QD with ribavirin (RBV) during Weeks 2 to 24.

Experimental: ALV 800 mg+RBV - Alisporivir (ALV) 600 mg BID with RBV for 1 week, followed by ALV 800 mg QD with RBV during Weeks 2 to 24.

Experimental: ALV 600 mg+PEG - Alisporivir (ALV) 600 mg BID with Peginterferon alfa-2a (PEG) for 1 week, followed by ALV 600 mg QD with PEG once weekly during Weeks 2 to 24.

Active Comparator: PEG+RBV - Peginterferon alfa-2a (PEG) and RBV during Weeks 1 to 24.


Treatment: drugs: Alisporivir
ALV 200 mg soft gel capsules administered orally

Treatment: drugs: Peginterferon alfa-2a
PEG 180 µg administered via subcutaneous (s.c.) injection once weekly

Treatment: drugs: Ribavirin
RBV 400 mg (2 x 200 mg tablets) administered orally twice daily (BID)

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Percentage of Participants With Rapid Viral Response (RVR) After 4 Weeks of Treatment &lt; the Limit of Quantification (RVR4LOQ) - RVR4LOQ was defined as RVR [serum hepatitis C virus (HCV) ribonucleic acid (RNA) &lt; the limit of quantification (LOQ), i.e., &lt; 25 IU/mL], after 4 weeks of treatment.</outcome>
      <timepoint>after 4 weeks of treatment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants With RVR After 4 Weeks of Treatment &lt; the Limit of Detection (RVR4LOD) - RVR4LOD was defined as Rapid Viral Response (RVR) [serum HCV RNA &lt; the limit of detection (LOD), i.e., &lt; 10 IU/mL], after 4 weeks of treatment.</outcome>
      <timepoint>after 4 weeks of treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants With RVR4LOQ and RVR4LOD (Genotype 2)</outcome>
      <timepoint>after 4 weeks of treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants With RVR4LOQ and RVR4LOD (Genotype 3)</outcome>
      <timepoint>after 4 weeks of treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants With Complete Early Viral Response (cEVR) After 12 Weeks of Treatment (cEVR12LOQ and cEVR12LOD) - cEVR12LOQ and cEVR12LOD were defined as cEVR [serum HCV RNA &lt; LOQ and &lt; LOD] after 12 weeks of treatment, respectively.</outcome>
      <timepoint>after 12 weeks of treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants With cEVR12LOQ and cEVR12LOD (Genotype 2)</outcome>
      <timepoint>after 12 weeks of treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants With cEVR12LOQ and cEVR12LOD (Genotype 3)</outcome>
      <timepoint>after 12 weeks of treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants With End of Treatment Response (ETR) Within 24 Weeks (ETR24LOQ and ETR24LOD) - ETR24LOQ and ETR24LOD were defined as ETR [serum HCV RNA &lt; LOQ and &lt; LOD] after 24 weeks of treatment or when prematurely discontinued.</outcome>
      <timepoint>at end of treatment, within 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants With ETR24LOQ and ETR24LOD (Genotype 2)</outcome>
      <timepoint>at end of treatment, within 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants With ETR24LOQ and ETR24LOD (Genotype 3)</outcome>
      <timepoint>at end of treatment, within 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants With RVR Who Achieved Sustained Viral Response (SVR) 12 Weeks After the End of Treatment (SVR12LOQ and SVR12LOD) - SVR12LOQ and SVR12LOD were defined as Sustained Viral Response (SVR) [serum HCV RNA &lt; LOQ and &lt; LOD] 12 weeks after treatment, respectively.</outcome>
      <timepoint>12 weeks after the end of treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants With RVR Who Achieved SVR12LOQ and SVR12LOD (Genotype 2)</outcome>
      <timepoint>12 weeks after the end of treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants With RVR Who Achieved SVR12LOQ and SVR12LOD (Genotype 3)</outcome>
      <timepoint>12 weeks after the end of treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants With RVR Who Achieved SVR at 24 Weeks After the End of Treatment (SVR24LOQ and SVR24LOD)</outcome>
      <timepoint>24 weeks after the end of treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants With RVR Who Achieved SVR24LOQ and SVR24LOD (Genotype 2)</outcome>
      <timepoint>24 weeks after the end of treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants With RVR Who Achieved SVR24LOQ and SVR24LOD (Genotype 3)</outcome>
      <timepoint>24 weeks after the end of treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants With On-treatment Viral Breakthrough - Viral breakthrough was defined as either:
Confirmed increase of HCV RNA =1 log10 above nadir (nadir = lowest HCV RNA value during treatment), or
HCV RNA becoming = 100 IU/mL after previously being undetectable (&lt; LOD) during treatment</outcome>
      <timepoint>within 24 weeks of treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants With Viral Relapse - Viral relapse was defined as having reappearance of detectable HCV RNA after previously being undetectable (&lt; LOD) during treatment.</outcome>
      <timepoint>within 24 weeks after the end of treatment</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion criteria:

          -  Chronic hepatitis C viral infection

          -  Plasma HCV RNA level lower limit = 10,000 IU/ml assessed by quantitative polymerase
             chain reaction (qPCR) or equivalent at screening (no upper limit)

          -  HCV genotype 2 or 3

          -  No previous treatment for hepatitis C infection</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion criteria:

          -  Evidence of cirrhosis at the time of screening

          -  Evidence of hepatocellular carcinoma at the time of screening

          -  Any other cause of relevant liver disease other than HCV

          -  Alanine aminotransferase (ALT) = 10 times upper limit of normal (ULN)

          -  Other protocol-defined inclusion/exclusion criteria may apply</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>340</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/05/2012</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,VIC</recruitmentstate>
    <hospital>Novartis Investigative Site - Kingswood</hospital>
    <hospital>Novartis Investigative Site - Kogarah</hospital>
    <hospital>Novartis Investigative Site - Westmead</hospital>
    <hospital>Novartis Investigative Center - Greenslopes</hospital>
    <hospital>Novartis Investigative Site - Clayton</hospital>
    <hospital>Novartis Investigative Site - Fitzroy</hospital>
    <postcode>2747 - Kingswood</postcode>
    <postcode>2217 - Kogarah</postcode>
    <postcode>2145 - Westmead</postcode>
    <postcode>4120 - Greenslopes</postcode>
    <postcode>3168 - Clayton</postcode>
    <postcode>3065 - Fitzroy</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Hawaii</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Hampshire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Bruxelles</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Gent</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Clichy Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Creteil</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Marseille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Frankfurt</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Freiburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hannover</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Leipzig</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Kerala</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Maharashtra</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Punjab</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Uttar Pradesh</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Guwahati</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Haryana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Hyderabad - Andhra Pradesh</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Mumbai</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>New Delhi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Bologna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Brescia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Pavia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Roma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Torino</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Pusan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Bialystok</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lódz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warsaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Puerto Rico</country>
      <state>San Juan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Kaohsiung</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Niaosong Township</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taichung</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Yun-Lin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Bangkok</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Chiang Mai</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Songkla</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Glasgow - Scotland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Plymouth</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Debiopharm International SA</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study is to investigate whether alisporivir (ALV; DEB025) alone or in combination with
      either ribavirin (RBV) or peginterferon alfa-2a (PEG) is more efficient compared to standard
      of care (PEG+RBV) in treatment-naïve participants with hepatitis C virus (HCV) genotype 2 and
      3. In addition, triple therapy with DEB025 plus standard of care will be applied to
      participants not achieving rapid viral response (RVR) in the different arms.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01215643</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Novartis Pharmceuticals</name>
      <address>Novartis Pharmaceuticals</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>